Insulin Pumps Market

The insulin pumps market is worth USD 7,590.0 million in 2025 and reaches USD 17,873.7 million by 2035, compounding at 8.94% a year. The figure is built bottom-up: roughly 2.2 million people using insulin pumps in 2025 across tubeless patch pumps, tubed durable pumps, infusion sets and reservoirs, and automated insulin delivery algorithms and software, at an average annual revenue of USD 3,450 per user covering the amortised pump and consumables, triangulated against diabetes prevalence, pump adoption data and manufacturer disclosures. Users grow 9.6% a year as automated insulin delivery improves outcomes and use extends to type 2 diabetes, while revenue per user eases 0.6% a year as competition and pharmacy channels spread. Continuous glucose monitoring sensors, covered in our separate sensor coverage, and hospital infusion pumps are excluded. This study sits within our diabetes devices coverage and follows the published Douglas Insights methodology.

How did pumps become an artificial pancreas?

By connecting to continuous glucose monitors and letting software adjust insulin automatically, which has changed insulin pumps from programmable syringes into systems that partly manage diabetes on their own. People with type 1 diabetes must replace the insulin their pancreas no longer makes, traditionally through several daily injections or a pump that delivers insulin continuously according to settings the user programs. Continuous glucose monitors now measure glucose every few minutes, and automated insulin delivery systems, often called hybrid closed loop systems, use algorithms to raise or lower insulin delivery in response to those readings, preventing many highs and lows without user action. Users still announce meals in most systems, which is why they are called hybrid, but the improvement in time spent in a healthy glucose range and the reduction in dangerous overnight lows have been substantial. As a result, automated insulin delivery has become the standard of care recommended by many diabetes guidelines, driving pump adoption. The exclusive chapter of this report tracks automated insulin delivery adoption by region and diabetes type, since it is the main driver of growth.

What does this market include?

This study covers insulin pumps and their dedicated consumables. Tubeless patch pumps cover pumps worn directly on the body that deliver insulin without tubing and are replaced every few days, the largest and fastest growing category. Tubed durable pumps cover pumps carried on a belt or in a pocket, connected by tubing to an infusion site, and used for several years. Infusion sets and reservoirs cover the disposable tubing, cannulas and insulin reservoirs used with durable pumps. Automated insulin delivery algorithms and software cover control software, apps and subscriptions associated with automated delivery. Continuous glucose monitoring sensors, covered in our separate glucose sensor coverage, insulin itself, insulin pens and syringes, and hospital infusion pumps, covered in our separate infusion pump coverage, sit outside the boundary. Value is measured at manufacturer realised revenue.

Will type 2 diabetes open a much larger market?

Potentially yes, because far more people have type 2 diabetes than type 1, and many of them use insulin, but uptake among them has so far been limited. Insulin pumps have mainly served people with type 1 diabetes, a relatively small population. Many people with type 2 diabetes eventually need insulin, often injected several times a day, and some of them could benefit from pumps, particularly simple patch pumps and automated systems that reduce the burden of multiple daily injections. Regulators have begun to clear automated insulin delivery systems for type 2 diabetes, and simple patch pumps designed for type 2 are available. However, cost, reimbursement and the effectiveness of newer drugs such as GLP-1 medicines, which reduce many people’s need for insulin, may limit the expansion. The model treats type 2 as a growing source of users, contributing meaningfully to volume, with the upside scenario capturing faster adoption.

What drives demand?

The first driver is automated insulin delivery. Better glucose control and quality of life from automated systems drive switching from injections to pumps.

The second driver is tubeless convenience. Patch pumps without tubing are easier to wear and have broadened the appeal of pump therapy.

The third driver is type 2 expansion. Regulatory clearance and simpler devices extend pump use to people with type 2 diabetes who use insulin.

The fourth driver is access. Pharmacy channel distribution and improving reimbursement make pumps easier to obtain in several markets.

What restrains the market?

Three restraints are modelled. Cost and reimbursement are the first: pumps and supplies are expensive, and coverage varies widely, limiting access in many countries. GLP-1 medicines are second: drugs that improve glucose control and reduce weight may lower insulin needs for many people with type 2 diabetes. Complexity and safety are third: pumps require training and carry risks such as insulin delivery interruption, and recalls have affected some products.

Which categories carry the value?

Tubeless patch pumps lead with 42% of 2025 value, USD 3,187.8 million, and grow fastest. Tubed durable pumps hold 30%, USD 2,277.0 million, with established automated systems. Infusion sets and reservoirs account for 20%, USD 1,518.0 million, recurring consumables for durable pumps. Automated insulin delivery algorithms and software contribute 8%, USD 607.2 million. Each category is modelled through 2035 by region.

Where are insulin pumps used?

North America dominates with 58% of 2025 value, USD 4,402.2 million, growing 8.07% a year, reflecting high pump adoption, strong reimbursement and pharmacy access. Europe holds 28%, USD 2,125.2 million, at 9.2%, with growing reimbursement for automated systems. Asia Pacific holds 10%, USD 759.0 million, and grows fastest at 12.0%, from low adoption in large populations. The Middle East contributes USD 151.8 million at 11.0%, Latin America USD 113.9 million at 10.4% and Africa USD 37.9 million at 9.6%. Six regional models sum to the global figure, with country tables in the Excel model.

Who makes insulin pumps?

Insulet leads tubeless patch pumps with its Omnipod systems, and Medtronic and Tandem Diabetes Care lead tubed durable pumps with automated insulin delivery. Beta Bionics, Roche, Ypsomed and others offer pumps and automated systems, and Chinese and Korean manufacturers supply regional markets. Pump makers partner with continuous glucose monitor makers such as Dexcom and Abbott to enable automated delivery. The competitive chapter profiles each manufacturer’s products, automated systems, sensor partnerships and regional presence.

How are insulin pumps priced?

Average revenue is USD 3,450 per user per year in 2025, combining pump hardware spread over its life with consumables. Durable pumps cost several thousand dollars upfront and last several years, with infusion sets and reservoirs purchased regularly, while patch pumps are bought as disposable units every few days, making their cost ongoing rather than upfront. Reimbursement and pharmacy benefit coverage strongly affect prices, and competition and pharmacy channels ease average revenue per user slightly. The pricing chapter publishes price bands by category.

How do the scenarios diverge by 2035?

The base case carries 9.6% growth in users and a 0.6% annual decline in revenue per user for an 8.94% revenue CAGR and USD 17,873.7 million in 2035. The GLP-1-headwind scenario, in which newer medicines limit insulin use and reimbursement tightens, sets the legs at 6.6% and minus 1.6%, landing near USD 12,240 million. The type-2-expansion scenario, in which automated insulin delivery spreads widely among people with type 2 diabetes, sets them at 12.0% and 0.4%, carrying the market past USD 24,530 million. Each 1-point change in user growth moves the 2035 figure by roughly USD 1,640 million.

Which rules and standards apply?

Three layers matter. Medical device regulation comes first: insulin pumps and automated delivery algorithms are regulated medical devices, and interoperability pathways allow compatible pumps, sensors and algorithms to be combined. Reimbursement is second: coverage decisions, including coverage through pharmacy benefits, largely determine adoption. Cybersecurity and data rules are third: connected pumps must meet cybersecurity requirements and health data protections. The regulatory chapter maps these requirements by jurisdiction.

Will fully automated systems remove the need to count meals?

Fully closed loop systems that need no meal announcements are the next goal, and some systems already reduce the burden by adapting automatically to meals, but insulin’s slow action limits how well any system can respond to eating without warning. Faster acting insulins, better algorithms and combinations with other hormones are being developed to move closer to a fully automatic artificial pancreas. The closer systems come to full automation, the more attractive pumps become compared with injections, particularly for children and people who struggle with daily management. The model treats continued algorithm improvement as supporting adoption throughout the forecast.

Douglas Exclusive: the automated insulin delivery adoption tracker

This report tracks, by region and diabetes type, insulin using populations, pump penetration, automated insulin delivery adoption, reimbursement status and device mix, converting diabetes epidemiology into pump users and revenue by category and region. Licence holders receive it as a maintained tab in the Excel model.

Methodology and receipts

The model is built bottom-up from users: type 1 and insulin using type 2 populations by region, pump penetration and automated delivery adoption, device and consumables revenue per user, and realised revenue from manufacturer disclosures, with glucose sensors, insulin, pens and syringes, and hospital infusion pumps excluded. Every figure carries a numbered source and a confidence grade in the fact sheet above, and the working model ships with every licence. The next scheduled review of this study is September 2027.